Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Webber, Elizabeth M ^a   Kauffman, Tia L ^a   O'Connor, Elizabeth ^a   Goddard, Katrina ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Genetic; Lynch syndrome; Meta analysis; Pharmacogenomic

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HEALTH IMPACT ASSESSMENT; HUMAN; META ANALYSIS; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; QUALITATIVE ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; PREDICTIVE VALUE;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; MICROSATELLITE INSTABILITY; PREDICTIVE VALUE OF TESTS;

EID: 84925678885     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1093-4     Document Type: Article

References (60)

1. American Cancer Society. What are the key statistics about colorectal cancer? Available at: http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics .
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558-61.
3. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-57.
4. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043-8.
5. Chu HY, Zheng QC, Zhao YS, Zhang HX. Homology modeling and molecular dynamics study on N-acetylneuraminate lyase. J Mol Model. 2009;15(3):323-8.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer (version 1.2013). Available at: www.nccn.org .
7. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. [Review] [86 refs]. J Clin Oncol. 2005;23(3):609-18.
8. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11-79.
9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European group on tumour markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-60.
10. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-27.
11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36.
12. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282(11):1054-60.
13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
14. Bradburn MJ, Deeks JJ, Altman DG. Metan-a command for meta-analysis in Stata. Meta-analysis in Stata: an updated collection from the Stata Journal. College Station, TX: Stata Press, 1998. p. 3-28.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
16. Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: A simulation study. Stat Methods Med Res. 2012;21(4):409-26.
17. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Sussex: Wiley; 2011.
18. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99(13):998-1003.
19. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for Industry Clinical Trial endpoints for the approval of cancer drugs and biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf . Accessed on: 7-30-2013.
20. Hong SP, Min BS, Kim TI, Cheon JH, Kim NK, Kim H, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer. 2012;48(8):1235-43.
21. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45(3):365-73.
22. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. [Erratum appears in J Clin Oncol. 2010 Oct 20;28(30):4664]. J Clin Oncol. 2010;28(20):3219-26.
23. Storojeva I, Boulay JL, Heinimann K, Ballabeni P, Terracciano L, Laffer U, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep. 2005;14(1):241-9.
24. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.[Erratum appears in J Clin Oncol. 2011 Jul 20;29(21):2949]. J Clin Oncol. 2011;29(10):1261-70.
25. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer, a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767-72.
26. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, et al. UKCCCR AXIS trial collaborators. Adjuvant. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer, a molecular study. Lancet. 2002;360(9343):1381-91.
27. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7(5):1343-9.
28. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. [Erratum appears in Clin Cancer Res. 2006 Jun 15;12(12):3868-9]. Clin Cancer Res. 2005;11(23):8332-40.
29. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126(2):394-401.
30. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol. 2006;24(15):2359-67.
31. Ohrling K, Edler D, Hallstrom M, Ragnhammar P. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Acta Oncol. 2010;49(6):797-804.
32. Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol. 2013;8:10.
33. Liang JT, Huang KC, Lai HS, Lee PH, Cheng YM, Hsu HC, et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer. 2002;101(6):519-25.
34. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rummele P, Hartmann A, et al. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer. 2006;118(9):2247-54.
35. Colombino M, Cossu A, Manca A, Dedola MF, Giordano M, Scintu F, et al. Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. Ann Oncol. 2002;13(9):1447-53.
36. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227(1):51-6.
37. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153-62.
38. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-70.
39. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57.
40. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy a meta-analysis of colorectal cancer survival data. [Review]. Eur J Cancer. 2010;46(15):2788-98.
41. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. [Review] [36 refs]. Eur J Cancer. 2009;45(10):1890-6.
42. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. [Review] [26 refs]. Anticancer Res. 2009;29(5):1615-20.
43. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
44. Bendardaf R, Lamlum H, Ristamaki R, Korkeila E, Syrjanen K, Pyrhonen S. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol. 2007;28(4):212-20.
45. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 2003;23(2C):1773-7.
46. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, Mitchell E, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 2004;24(5B):3161-7.
47. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009;101(6):998-1004.
48. Des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.[Erratum appears in Anticancer Res. 2007 Sep-Oct;27(5b):3667]. Anticancer Res. 2007;27(4C):2715-9.
49. Ismail AS, Quinn MG, Wright MA, Ernst A, Kao V, Grogan L, et al. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. Oncol Rep. 2005;13(6):1145-52.
50. Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci. 2011;102(9):1706-11.
51. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol. 2010;27(4):1277-85.
52. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266-73.
53. Muller CI, Schulmann K, Reinacher SA, Andre N, Arnold D, Tannapfel A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008;23:1033-9.
54. Rosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer. 2001;95(3):162-7.
55. Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014;20(15):4230-43.
56. Kim JH, Kim KJ, Rhee YY, Oh S, Cho NY, Lee HS, et al. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer. Mod Pathol. 2014;27(3):443-53.
57. Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 2014;146(2):401-11.
58. Cohen SA. Current lynch syndrome tumor screening practices: a survey of genetic counselors. J Genet Couns. 2014;23(1):38-47.
59. Recommendations from the EGAPP Working Group. Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35-41.
60. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.